Products for Research Use Only

Lidocaine-d6

CAT: 0804-HY-B0185S2Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0185S2Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lidocaine-d6 (Lignocaine-d6) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].
CAS Number
1215823-29-2
Product Name Alternative
Lignocaine-d6
UNSPSC
12352005
Target
Apoptosis; ERK; Isotope-Labeled Compounds; MEK; NF-κB; Sodium Channel
Related Pathways
Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Others; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Cardiovascular Disease
Smiles
O=C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])CN(CC)CC
Molecular Formula
C14H16D6N2O
Molecular Weight
240.37
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[3]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[4]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported